Rheumatoid Arthritis Market Size, Share, Global Insights and Analysis

Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Rheumatoid Arthritis pipeline therapeutics constitutes close to 470 molecules. Out of which approximately 423 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 13, 28, 45, 58, 11, 215, 47 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 33 and 13 molecules, respectively.

Browse full report with TOC@ https://marketreportscenter.com/reports/338304/rheumatoid-arthritis-pipeline-review-h1-2016

Global Markets Direct's latest report Rheumatoid Arthritis – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Rheumatoid Arthritis - Pipeline Review, H1 2016...